Javier Cortés
Impact in
- Oncology top 0.01%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 581
- HER2/EGFR in Cancer Research 303
- Cancer Treatment and Pharmacology 276
- Cancer Immunotherapy and Biomarkers 83
- Colorectal Cancer Treatments and Studies 53
-
- Advanced Breast Cancer Therapies 243
- Co-authors
- José Baselga (24 shared papers)Graham Ross (12 shared papers)Nadia Harbeck (66 shared papers)Sandra M. Swain (22 shared papers)Emma Clark (13 shared papers)José Baselga (48 shared papers)Sung‐Bae Kim (28 shared papers)Fátima Cardoso (30 shared papers)
- Journals
- Journal of Clinical Oncology (151 papers)Cancer Research (109 papers)Annals of Oncology (98 papers)ESMO Open (24 papers)European Journal of Cancer (18 papers)
- Partner nations
- SpainUnited StatesUnited Kingdom
In The Last Decade
Javier Cortés
697 papers receiving 28.0k citations
Javier Cortés's Hit Papers
Peers
Comparison fields: 5 of 170
- Oncology 21.1k
- Cancer Research 8.0k
- Pulmonary and Respiratory Medicine 8.8k
- Radiology, Nuclear Medicine and Imaging 5.3k
- Genetics 1.8k
Countries citing papers authored by Javier Cortés
This map shows the geographic impact of Javier Cortés's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Cortés with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Cortés more than expected).
Fields of papers citing papers by Javier Cortés
This network shows the impact of papers produced by Javier Cortés. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Cortés. The network helps show where Javier Cortés may publish in the future.
Co-authors
The 25 scholars most cited alongside Javier Cortés, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 726 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Breast cancer Hit paper breakdown → | 2019 | 1983 |
| 2 | Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer Hit paper breakdown → | 2011 | 1773 |
| 3 | Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer Hit paper breakdown → | 2015 | 1421 |
| 4 | Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Hit paper breakdown → | 2011 | 807 |
| 5 | Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) Hit paper breakdown → | 2013 | 774 |
| 6 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Hit paper breakdown → | 2013 | 700 |
| 7 | Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Hit paper breakdown → | 2010 | 700 |
| 8 | Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer Hit paper breakdown → | 2007 | 659 |
| 9 | Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer Hit paper breakdown → | 2022 | 594 |
| 10 | Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer Hit paper breakdown → | 2016 | 511 |
| 11 | MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer Hit paper breakdown → | 2017 | 490 |
| 12 | Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy Hit paper breakdown → | 2010 | 456 |
| 13 | Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 348 |
| 14 | 2015 | 333 | |
| 15 | Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 330 |
| 16 | 2013 | 303 | |
| 17 | 2014 | 284 | |
| 18 | Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study Hit paper breakdown → | 2020 | 279 |
| 19 | Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies Hit paper breakdown → | 2021 | 275 |
| 20 | 2014 | 260 |
About Javier Cortés
Javier Cortés is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 726 papers that have together received 28.6k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (303 papers), Cancer Treatment and Pharmacology (276 papers), Advanced Breast Cancer Therapies (243 papers), Breast Cancer Treatment Studies (170 papers), Cancer Immunotherapy and Biomarkers (83 papers), Monoclonal and Polyclonal Antibodies Research (70 papers), Cancer Genomics and Diagnostics (59 papers) and Colorectal Cancer Treatments and Studies (53 papers). The work is most often cited by research in Oncology (21.1k citations), Cancer Research (8.0k citations), Pulmonary and Respiratory Medicine (8.8k citations), Radiology, Nuclear Medicine and Imaging (5.3k citations) and Genetics (1.8k citations). Javier Cortés has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include José Baselga, Graham Ross, Nadia Harbeck, Sandra M. Swain, Emma Clark, José Baselga, Sung‐Bae Kim, Fátima Cardoso, Andreas Schneeweiß and Mark Benyunes. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, ESMO Open and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.